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Abstract
Genetic defects that affect intestinal epithelial barrier function can present with very early onset 
inflammatory bowel disease (VEOIBD). Using whole genome sequencing, a novel hemizygous 
defect in NOX1 encoding NAPDH oxidase 1 was identified in a patient with ulcerative colitis-like 
VEOIBD. Exome screening of 1,878 paediatric patients identified further seven male IBD patients 
with rare NOX1 mutations. Loss-of-function was validated in p.N122H and p.T497A, and to a 
lesser degree in p.Y470H, p.R287Q, p.I67M, p.Q293R as well as the previously described 
p.P330S and the common NOX1 SNP p.D360N (rs34688635) variant. The missense mutation 
p.N122H abrogated reactive oxygen species (ROS) production in cell lines, ex-vivo colonic 
explants and patient-derived colonic organoid cultures. Within colonic crypts, NOX1 constitutively 
generates a high level of ROS in the crypt lumen. Analysis of 9,513 controls and 11,140 IBD 
patients of non-Jewish European ancestry did not reveal an association between p.D360N and 
IBD. Our data suggest that loss-of-function variants in NOX1 do not cause a Mendelian disorder 
of high penetrance but are a context specific modifier. Our results implicate that variants in NOX1 
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change brush border ROS within colonic crypts at the interface between the epithelium and 
luminal microbes.
Introduction
In the gastrointestinal tract, the epithelium is the primary barrier separating the high density 
of microbes in the intestinal lumen from the immune cells in the lamina propria. Defects in 
epithelial barrier function predispose to inflammatory bowel disease (IBD) in humans and 
cause intestinal inflammation in animal models.1, 2
Genetic risk variants for IBD in loci linked to genes relevant for epithelial integrity have 
been identified by genome wide association studies (GWAS) studies (e.g. GNA12, HNF4A, 
MUC19 or XPB1).3, 4 In addition, there is an expanding group of monogenic defects 
associated with significant functional impact on intestinal epithelial barrier function.5, 6 
Defects in intestinal epithelial guanylcyclase gene GUCY2C or the solute carrier family 9 
member 3 (SLC9A3) encoding the sodium hydrogen exchanger NHE3 cause congenital 
diarrhea and Crohn’s disease-like intestinal inflammation in approximately 30% of cases.7, 8 
Likewise, defects in IKBKG causing impaired NF-κB signaling result in epithelial apoptosis 
and intestinal inflammation.9 In patients with TTC7A-deficiency, defects in epithelial PI4K 
and Rho signaling cause disturbed epithelial polarization leading to multiple intestinal 
atresia or very early onset intestinal inflammation.10–12
Recently, we reported a common NOX1 missense mutation associated with ulcerative colitis 
(UC) in males of Ashkenazi Jewish ancestry, in addition to a rare NOX1 mutation in a 
patient with early onset of intestinal inflammation.13 NOX1 is the catalytic subunit of 
superoxide-generating nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
complex 1, and is comprised of NOX1, p22phox, NOXA1, NOXO1 and Rac1-GTP.14–16 
NOX1 is a close structural homologue of NOX2, the catalytic subunit of the multimeric 
NADPH oxidase complex 2 (NOX2, p22phox, p67phox, p47phox, p40phox and Rac2-GTP), the 
enzyme responsible for the microbicidal ‘respiratory burst’ in phagocytes. However, in 
contrast to NOX2, NOX1 is located in the membrane of the intestinal epithelial cells17–21 
and, may have additional functions in endothelial cells and in non-gastrointestinal 
epithelium.22
Here, we investigate several loss-of-function missense variants in NOX1 that were identified 
by whole genome and whole exome sequencing in patients with VEOIBD. We identified 
eight males with six hemizygous non-synonymous NOX1 variants, with variable functional 
impact upon reactive oxygen species (ROS) production as compared to the previously 
described p.P330S and the common p.D360N (rs34688635) variants. We identified two 
variants with nearly complete loss-of-function and a further four variants with reduced 
activity. Primary patient-derived intestinal colonic organoids of the loss-of-function variant 
p.N122H were used to validate those findings.
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We studied a male patient of Caucasian origin who presented with bloody stools and failure 
to thrive at the age of two years (Table 1). He was diagnosed with IBD at the age of five 
years. His disease progressed from proctitis to pancolitis at the age of eight years without 
upper gastrointestinal involvement (Figure 1a). Histological examination of colonic 
specimens showed crypt architectural distortion, cryptitis and crypt abscess formation 
(Figure 1a). Histologic assessment of epithelial cell proliferation or goblet cell formation did 
not reveal marked differences compared to inflammatory controls (Supplementary Figure 
S1). The patient required oral corticosteroid therapy at diagnosis, followed by thiopurine and 
then methotrexate therapy. After years of poorly controlled inflammation, mucosal healing 
was achieved with anti-TNF therapy (adalimumab). Nine years after diagnosis, his disease 
was complicated by Epstein Barr virus-associated haemophagocytic lymphohistiocytosis 
(HLH) whilst on azathioprine therapy, requiring intensive care therapy. Mutations in XIAP 
and SAP were excluded at that time. There was no family history of IBD.
Whole genome sequencing of the patient led to the identification of a novel hemizygous 
variant in the NADPH oxidase 1 NOX1; NM_007052; c.A364C; p.N122H (Supplementary 
Figure S2). The mutation was validated with Sanger sequencing and inherited in an X-linked 
manner from the patient’s mother (Figure 1b). The mutation is not present in 1,678 CD, 
1,089 UC patients or 1,862 non-IBD controls, or in any public exome database covering an 
excess of 120,000 human alleles (e.g. 1000 Genomes, Exome Aggregation Consortium 
ExAC), thus supporting the view that this is an extremely rare genetic variant 
(Supplementary Table 1). The amino acid N122 is located in the 3rd transmembrane domain 
and is evolutionary highly conserved across species (Figure 1c). In silico analysis by several 
tools including SIFT, PolyPhen-2 and CADD,23 predicted that the mutation causes a loss-of-
function (Supplementary Table 2). Furthermore, the p.N122H variant affects all known 
isoforms of NOX1 (Figure 1d). Other hemizygous, homozygous or compound heterozygous 
variants in the index patient were considered unlikely pathogenic (Supplementary Table 3). 
None of these variants have been described as causative for IBD or EBV-induced 
hemophagocytosis.
NOX1 expression and epithelial-derived ROS
To understand the relative distribution of ROS-generating NADPH oxidases in the human 
gastrointestinal tract and to compare non-inflamed homeostasis with inflammatory 
conditions, we determined the mRNA expression pattern of several NADPH oxidases and 
their subunits. Consistent with previous literature,17–20 NOX1 is highly expressed in the 
colonic epithelium with a gradient from ileum to the distal colon (Figure 1e). The subunits 
NOXA1 and NOXO1 are constitutively expressed along the human gastrointestinal tract 
(Figure 1e). Whereas phagocytic NOX2 can be detected even in the non-inflamed mucosa, 
we observed no expression of NOX4 and very low expression of NOX5 (Supplementary 
Figure S3a). In parallel with the NOX1 expression gradient, we found increased ROS 
generation in ex vivo biopsies obtained from lower compared to the upper gastrointestinal 
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tract suggesting that NOX1 is the primary source of superoxide in the non-inflamed colonic 
epithelium (Supplementary Figure S3b,c).
We visualized superoxide production of colonic crypts ex vivo using nitroblue tetrazolium 
chloride (NBT). Reaction of NBT with superoxide results in formation of water-insoluble 
blue formazan precipitates which can be observed by light microscopy (Figure 1f). 
Following 60 minutes incubation, we observed the deposition of formazan at the outer 
margin of colonic crypts indicating the constitutive release of superoxide from the colonic 
epithelium into the crypt lumen (Figure 1f). Co-incubation with ML17124 or DPI, both 
NADPH-oxidase inhibitors, suggested a reduction of superoxide production (Figure 1g). 
This finding was confirmed by the luminescence assay (Figure 1h).
Ex-vivo NOX1 biopsy and primary organoids
To assess the functional consequences of p.N122H mutation on colonic epithelial ROS 
production, we first assessed superoxide release in ex vivo colonic biopsies from the index 
patient and compared those to biopsies from patients with IBD and non-inflamed controls. 
Although biopsies from the NOX1 p.N122H variant patient generated low level of 
superoxide, this was within the range seen in other patients with quiescent IBD and non-
inflamed controls (Figure 2a). However, since phagocytes that express NOX2 are present in 
non-inflamed biopsies (Supplementary Figure S3a) and lamina propria infiltrating 
phagocytes likely contribute to ROS measurements in IBD patient biopsies, the assay 
specificity is limited and an epithelial NOX1 defect is potentially masked.
NOX1 p.N122H reduces ROS production in primary organoids
To validate the functional impact of the genetic defect in epithelial cells, we generated 
primary epithelial organoids from colonic biopsy specimens of the NOX1 p.N122H patient, 
a male IBD control patient and a healthy female control without IBD (Figure 2b). Both IBD 
patients were in clinical remission at the time of the endoscopy. Colonic organoids express 
NOX1 mRNA, along with its subunits NOXA1 and NOXO1 and this expression did not 
differ between the index p.N122H patient and the IBD control patient (Figure 2c). We found 
high DUOX2 mRNA expression but only minimal NOX2 expression in the colonic epithelial 
organoids reflecting the epithelial origin and the absence of phagocytes (Supplementary 
Figure S3a).
Colonic epithelial organoid cells carrying NOX1 p.N122H mutation produced significantly 
less constitutive superoxide than control organoid cells derived from the IBD patient or a 
patient without inflammatory disease (Figure 2d). Of note, whereas PMA stimulation 
increased superoxide generation by control organoids, PMA stimulation of NOX1 p.N122H 
organoids did not. Even after stimulation with PMA, superoxide production by NOX1 
p.N122H organoids was significantly less than baseline ROS of IBD control organoids 
(Figure 2d).
Functional characterization of multiple NOX1 hemizygous variants in VEOIBD
To find additional NOX1 variants in patients with VEOIBD we screened exomes of 1,878 
pediatric IBD patients. We identified 5 additional non-synonymous variants in NOX1 in 
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separate patients in whom no other known or plausible genetic monogenic diagnosis was 
established (Table 1). The missense variants were predicted to be damaging by SIFT, 
PolyPhen-2 or CADD scores and were rare (MAF<1%) genetic variants (Supplementary 
Tables 1 and 2). All variants changed conserved amino acids (Supplementary Figure S4) and 
were found in regions with significant homology between NOX1 and NOX2 (Supplementary 
Figure S5).
To characterize the functional impact of those variants we transfected the multimeric 
NADPH oxidase complex 1 in the colonic epithelial cell line HCT116. Alongside the rare 
NOX1 variants p.N122H, p.I67M, p.R287Q, p.Q293R, p.Y470H and p.T497A that we 
identified in this study, we tested the previously described p.P330S variant13 and the 
common polymorphism p.D360N (allele frequency European-non-Finnish, 2.4%). Three 
variants in patients P14, P15 and P16 affected potential splice sites which we could not 
assess functionally (Supplementary Tables 1, 2 and 4). We used HCT116 cells since these 
cells express only low levels of NOX1 subunits (data not shown) and endogenous ROS 
generation cannot be detected (Figure 3a). Co-expression of wild-type NOX1 together with 
the subunits NOXA1 and NOXO1 resulted in superoxide generation in unstimulated and 
PMA-stimulated condition (Figure 3a,b). In contrast, co-expression with NOX1 variants 
variably diminished ROS generation. Whereas NOX1 variants p.N122H (index patient) and 
p.T497A completely abrogated both spontaneous and PMA-induced ROS production, the 
NOX1 variants p.I67M, p.R287Q, p.Q293R, p.P330S, p.D360N (common polymorphism) or 
p.Y470H were observed to either decrease spontaneous ROS and/or diminish PMA-
stimulated ROS (Figure 3a,b). Expression levels of wild-type and variant NOX1 constructs 
were comparable (data not shown). This suggests that the rare genetic variants affected the 
ROS production to a variable degree between complete loss-of-function and moderate 
reduction comparable to polymorphisms.
Characteristics of patients with loss-of-function NOX1 variants
We analyzed the IBD phenotype in all male patients with confirmed loss-of-function NOX1 
variants (Table 1 and Supplementary Table 4). Out of the 10 male patients with hemizygous 
NOX1 mutations, four presented with CD, three with UC and three with IBDU. In 
congruency with NOX1 expression, disease location was always colonic, with two patients 
also having perianal disease. Median age of onset was 7.9 years (range 1.8 to 10.5 years). 
Medical treatment included corticosteroids, aminosalicylates, azathioprine, methotrexate or 
anti-TNF (infliximab or adalimumab in 4 of 8 patients) and one patient underwent ileocecal 
resection for stricture. No infections with intestinal pathogens were recorded. With 
exception of the index patient, no other severe HLH/EBV-driven pathologies were recorded.
Population based characteristics of genetic loss of function NOX1 variants
In addition to those rare variants in NOX1, common polymorphisms might similarly 
contribute to IBD susceptibility. Of note, the common NOX1 polymorphism p.D360N has 
recently been associated with UC in Ashkenazi Jewish males.13 To determine whether this is 
Ashkenazi Jewish-specific or an association across several populations, we performed a 
genetic analysis of individuals of non-Jewish European ancestry. Although we observed a 
trend in the US European ancestry cohort (Table 2 and Supplementary Tables 5 and 6), 
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neither analysis of allele counts in UK cohorts nor analysis of summed allele counts from a 
total of 9,513 healthy controls and 11,140 IBD patients revealed an association (Table 2). 
This suggests that the association of NOX1 p.D360N with UC in males is not present across 
different populations. Variation is also reflected by a variable distribution of p.D360N allele 
frequency across populations (Figure 4a).
To further understand the importance of NOX1 variation, we compared the frequency of 
hemizygous NOX1 missense and NOX1 loss-of-function variants (STOP codon, frameshift, 
predicted splice site), with those in NOX2, the causative gene of most patients with chronic 
granulomatous disease. The frequency of genetic missense variation in NOX1 is higher as 
compared to the homologous NOX2 (Figure 4b). Similarly, the constraint metric based on 
the ExAC dataset indicates that loss-of-function variants in NOX1 are tolerated as indicated 
by a probability of being loss-of-function intolerant25 (pLI) of 0 (Figure 4c). In contrast 
NOX2 is extremely intolerant to any loss-of-function variation (pLI 0.998)25 as are many 
other genes causing X-linked primary immunodeficiencies (Figure 4c). This suggests that 
NOX1 underwent less evolutionary pressure as compared to NOX2 or other X-linked 
immunodeficiency genes.
In summary, our data suggest that NOX1 is the key NADPH oxidase for baseline ROS in 
human colonic crypt epithelium. Complete loss-of-function variants in NOX1 are rare and 
not associated with a distinct IBD sub-phenotype. Population statistics suggest that loss-of-
function variants in NOX1 are rare but likely tolerated.
Discussion
In this study we investigated rare X-linked variants in NOX1 in eight male IBD patients. 
Functional analysis suggests a variant-dependent loss of NOX1-mediated superoxide 
generation. The clinical phenotype of affected patients was early onset of IBD with 
progressive and severe colonic disease, refractory to conventional therapy. The affected 
cohort demonstrates that NOX1-dependent ROS production is essential for superoxide 
production in colonic crypts.
Our characterization of six rare variants in NOX1 (p.I67M, p.N122H, p.R287Q, p.Q293R, 
p.Y470H and p.T497A) expands the recent description of the rare NOX1 variant p.P330S 
and the common NOX1 polymorphism p.D360N in two male VEOIBD patients.13 
Furthermore, the NOX1 variant p.R287Q, which is functionally characterized in this study, 
has also been described but not characterized in an independent cohort of children with 
VEOIBD, adding further weight to the significance of epithelial NOX1.26
Diverse mechanisms maintain intestinal epithelial integrity, which serves as a critical barrier 
to luminal bacteria, viruses and fungi.1, 2 Amongst these, NOX1 is likely to play a relevant 
role.27, 28 The generation of superoxide by NOX1 at the colonic epithelial border may have 
an anti-adhesive or anti-invasive effect on bacteria, contributing to the barrier function of the 
inner mucus layer within colonic crypts. Indeed, our data confirm previous findings that the 
gene expression of NOX1 follows the density of bacterial colonization in the gastrointestinal 
tract.17–20 Reduced generation of superoxide due to genetic variants in NOX1 may affect 
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crypt homeostasis allowing subsequent crypt colonization by luminal microbiota. NOX1-
derived superoxide also influences intestinal epithelial differentiation and goblet cell 
function.29–31 Colonic mucus produced by goblet cells provides an important barrier 
between the intestinal microbiota and the colonic epithelium, maintaining sterility at the 
epithelial border.32
The importance of NADPH oxidases for barrier function is also exemplified by DUOX2, an 
NADPH oxidase family member, which is expressed throughout the GI tract. Notably, 
defects in DUOX2 have been recently described as a potential susceptibility factor in 
patients with VEOIBD.13, 33 In animal models, defects in the Drosophila duox2 homolog or 
in Zebrafish increased susceptibility against enteropathogens.34, 35 Whereas Duoxa−/− mice 
on thyroid hormone replacement showed normal growth and no evident phenotype,36 recent 
studies suggested that colonization of segmented filamentous bacteria in the ileum, bacterial 
translocation into mesenteric lymph nodes, and Salmonella typhimurium systemic 
dissemination, is dependent on DUOX activity.37 Although DUOX2 expression is inducible 
and is increased in patients with intestinal inflammation33, 38 thereby potentially 
contributing to epithelial stress and intestinal tissue damage, these data indicate that DUOX 
activity may a functional mechanism that restricts bacterial colonization at the mucosal 
interface.
Interestingly, NOX1 activity regulates DUOX2 expression in the intestinal epithelium during 
C. rodentium infection.39 Although loss of epithelial Cyba protected against C. rodentium 
and L. monocytogenes infection, this is likely an indirect effect due to the resulting 
overgrowth of H2O2-producing lactobacilli.39 This suggests an unexpected level of 
functional hierarchy and complex collaboration between NOX1 and DUOX2.39
Despite the complete loss of brush border ROS that has been observed in two NOX1 variants 
(p.N122H and p.T497A), we have not observed an increased susceptibility to intestinal 
infections such as Salmonella or Yersinia. This is in agreement with recent data suggesting 
that lack of Nox1 does not affect infection susceptibility in a mouse model of Salmonella 
typhimurium-induced typhlitis.40 Nonetheless, larger patient numbers with complete loss-of-
function NOX1 variants are required to more definitively determine the impact of these 
mutations on susceptibility to infection. Interestingly, the patient with the p.N122H mutation 
developed severe HLH in the context of EBV infection whilst on azathioprine therapy.41 
Viral spreading has been shown to be increased in Nox1-deficient mice infected with 
influenza virus,42 implicating a role for NOX1 in viral control. Again, larger patient 
numbers are required to fully understand the penetrance of the NOX1 variant phenotype.
Given the relatively high load of non-synonymous mutations of NOX1 compared to NOX2 
and the large number of DUOX2 mutations in humans, it is likely that NOX/DUOX 
enzymes have partially redundant functions. It is therefore likely that both NOX1 and 
DUOX2 play a role in susceptibility to intestinal inflammation, and loss-of-function variants 
alone cause not highly penetrant Mendelian type disorders. In keeping with a second hit 
hypothesis, Nox1-deficiency in Il10-deficient mice resulted in earlier and more severe 
intestinal pathology, but loss of Nox1 alone did not cause intestinal inflammation.30 
Similarly, patients with congenital secretory diarrhea due to activating mutations in the 
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guanylate cyclase C (GC-C)7, 43 or inactivating mutations in SLC9A3 encoding for the 
sodium/proton exchanger NHE3,8 a downstream target of GC-C, may also present with an 
IBD phenotype. In these patients the decreased epithelial uptake of sodium results in 
changes of mucosal ion content and pH, and Nhe3-deficiency in mice leads to an altered 
composition of the intestinal microbiota.44, 45 This dysbiosis drives intestinal inflammation 
in a T cell-dependent model of intestinal inflammation.46 Our studies suggest that loss of 
ROS at the colonic crypt may have a similar effect on barrier function.
Altogether these data suggest a highly context specific role of epithelial NADPH oxidases in 
intestinal homeostasis. Whilst in some animal models, a lack of Il10 and Nox1 increases 
epithelial stress and susceptibility to colitis30, in other instances, lack of NADPH oxidase 
activity is protective. Indeed a protective role of Nox1 and Duox2 is suggested in a mouse 
model of ileocolitis caused by lack of protective glutathione peroxidase factors.47–49 In this 
model GPx1- and GPx2-knockout leads to oxidative stress caused by Nox1 and Duox2 with 
a dominant role of Nox1 for crypt epithelial apoptosis.48, 49 This oxidative stress is 
dependent on the presence of the intestinal microbiota since germ free mice are protected 
and colitis develops within one week of bacterial colonization.50 Given the role of NOX1 as 
a modifier of intestinal microbiota, we can only speculate whether IBD patients with loss-of-
function NOX1 variants would benefit from therapeutic microbiome-altering strategies (e.g. 
antibiotics, nutrition, probiotics or fecal transplant). Further studies characterizing the 
human gut microbiota in the setting of NOX1 deficiency are required.
It is possible that the human population genetics reflect this context specific role of NOX1. 
Whereas in populations like Ashkenazi Jews, the hemizygous NOX1 p.D360N variant is 
associated with UC, in European descent populations it is not. Substantially stronger genetic 
variation of NOX1 compared to NOX2 suggests that the overall impact on disease 
susceptibility of these genes is significantly different despite the high degree of protein 
conservation and similarity. It is even possible, that the degree of genetic variation in NOX1 
is caused by environmental factors such as infections where reduced ROS is protective.
In conclusion, we report six novel variants in the NOX1 gene in patients with IBD, two of 
which are associated with complete loss-of-function of the gene product and with loss of 
ROS production. Our study illustrates the complexity of epithelial barrier function in the 
pathogenesis of IBD and the need better to understand the functional impact of ROS 
production at the colonic crypt epithelium as a cause of colonic inflammation.
Methods
Human subjects
The recruitment of participants was approved by relevant ethics committees or institutional 
review boards at the individual contributing institution. Written informed consent was 
obtained from all patients/legal guardians and healthy controls.
Patients with IBD (including the index patient P1) and controls without intestinal 
inflammation were prospectively recruited as a part of the Oxford IBD cohort study or the 
Oxford Gastrointestinal Illness Biobank (REC 09/H1204/30 & REC 11/YH/0020). 
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Replication genotyping of the p.N122H variant was performed in 2,767 IBD patients and 
1,862 non-IBD controls. These individuals were enrolled by the UK IBD Genetics 
Consortium (http://www.ibdresearch.co.uk/). Exomes of 1,878 pediatric onset IBD patients 
without genetic diagnosis were screened for additional rare NOX1 variants. Samples were 
previously genotyped as part of the COLORS in IBD study (n = 150; Oxford, UK), the 
NEOPICS consortium (n = 545; Toronto, Canada, www.neopics.org) or the RISK cohort51 
(n = 1,183; Atlanta, USA). Genetic association testing of NOX1 p.D360N (rs34688635) was 
conducted on genotype data from IBD patients of non-Jewish European ancestry from the 
following cohorts: the European ancestry exome chip dataset52 (n = 10,523), the Oxford 
IBD cohort study (n = 513) and the COLORS in IBD study (n = 104). Sequence data from 
healthy individuals were obtained from the European ancestry exome chip dataset52 (n = 
5,726) and the INTERVAL study (n = 4,436; www.intervalstudy.org.uk). Population controls 
were also obtained from the UK10K project (www.uk10k.org).
Genotyping
Whole genome sequencing and NOX1 variant p.N122H identification—The 
index mutation in NOX1 was identified by whole genome sequencing as part of the 
WGS500 project.53 DNA was analyzed from peripheral blood mononuclear cells. In 
summary, whole genome sequencing was performed on 3.5–7.5 ng DNA on either the 
Illumina HiSeq2000 or the HiSeq2500 run in standard mode using v2.5 or v3 sequencing 
chemistry. The genomic DNA was fragmented, end-paired, A-tailed and adapter-ligated 
before size selection and amplification for a multiplexed library preparation as described in 
Taylor et al.53 The libraries were paired end sequenced and sequenced to an average 
coverage between 27 and 40 quality reads per base. Resulting 100 base pair reads were 
mapped to the GRCh37d5/hg19 human reference sequence using Stampy and the SNVs and 
short InDels were called with Platypus.54 Variant files were analyzed using QIAGEN’s 
Ingenuity® Variant Analysis™ software (www.qiagen.com/Ingenuity, QIAGEN Redwood 
City). High quality calls were analyzed. For candidate analysis, we investigated a gene list of 
known variants associated with monogenic forms of IBD.5 Filters for variant frequency 
(<1%; 1000 Genomes Project) and predicted deleterious filters (SIFT and PolyPhen) were 
applied to prioritize high quality calls for non-synonymous and likely pathogenic variants.
Replication genotyping of the p.N122H variant—Replication genotyping on the 
Sequenom plex was carried out at the Sanger Institute.
Whole exome sequencing—Regeneron performed whole exome sequencing on a cohort 
of 1,183 probands with pediatric onset IBD (ages 0–18.5 years), including their affected and 
unaffected parents and siblings, where available (total samples = 2,704). Sample preparation, 
whole exome sequencing, and sequence data production were performed as previously 
described.55 The exomes of RISK cohort study participants (n = 545) were captured using 
SureSelect Human All Exon kit v2 (Agilent Technologies), using 3 µg of genomic DNA. 
Subsequently, captured libraries were sequenced on Illumina HiSeq2000 by 100-base pair 
paired-end (PE) sequencing. Image processing and base calling was performed using 
standard Illumina software. Raw sequence reads were mapped relative to the human genome 
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reference sequence (GRCh38/hg38) using the PEMapper software tool (Cutler DJ et al, 
submitted) to identify single nucleotide variants (SNVs).
Sanger sequencing—NOX1 variants were validated using Sanger sequencing according 
to standard techniques.
Histology
Historic routine haematoxylin and eosin histology sections from the patient identified to 
harbor the NOX1 p.N122H mutation and IBD controls were analyzed. Staining of goblet 
cells or the proliferation marker Ki67 was performed on archived paraffin-embedded colonic 
epithelial biopsies. Specimens were stained using an Alcian blue and periodic acid-Schiff’s 
reagent staining kit (Clin-Tech Limited, UK) or rabbit monoclonal antibody to Ki67 (clone 
SP66, AbCam, Cambridge, USA), respectively. Nuclear fast red and haematoxylin (Sigma-
Aldrich, Gillingham, UK) were used to counterstain cell nuclei.
Protein sequence alignment
Multiple sequences were aligned using ClustalW2.56 Data were obtained from the National 
Center for Biotechnology Information (NCBI). Sequence alignment is based on the 
following accession numbers: Danio rerio, NP_001095857.1; Xenopus tropicalis, 
XP_002939249.2; Gallus gallus, NP_001095300.1; Mus musculus, NP_757340.1; Homo 
sapiens, NOX1 isoform 1–3, NP_008983.2, NP_039249.1 and NP_001258744.1; Homo 
sapiens, NOX2, NP_000388.2.
Expression analysis
Colonic biopsies were stored in RNAlater (Qiagen) prior to analysis. RNA was extracted 
using RNAeasy kit (Qiagen), transcribed in cDNA with High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) and expression data were obtained using TaqMan 
primers (Life Technologies) for NOX 1–5, NOXO1, NOXA1, DUOX1 and DUOX2. Results 
were normalized to GAPDH expression. Relative gene expression was calculated using the 
ΔCt method.
Colonic epithelial organoid cultures
Human colon crypts were isolated and organoids were cultured as previously described.57 
Briefly, crypts were embedded in Cultrex® Reduced Growth Factor Basement Membrane 
Extract, (BME) Type 2 RGF PathClear (Amsbio) and seeded in 48-well plates. The BME 
was polymerized for 10 minutes at 37°C, and 250 µL/well of organoid culture media was 
added. Organoid culture media consisted of advanced Dulbecco’s modified eagle 
medium/F12 supplemented with penicillin/streptomycin (10 mmol/L), HEPES (1 M), 
Glutamax (10 mmol/L) and the following growth factors: Wnt conditioned media (50%) 
B27 (1×), EGF (50 ng/mL), Noggin (10%), R spondin (20%), gastrin (10 nM), Nicotinamide 
(10 mM), A83-01 (500 nM) and SB202190 (10 µM). Y-27632 (10 µmol/L; Sigma) was 
included in the medium for the first five days in culture. Once organoid growth was 
established, the culture media was refreshed every three days.
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Transfection of HCT116 cells
The colonic epithelial cell line HCT116 was maintained in McCoy's 5A Modified (Gibco) 
supplemented with 10% fetal bovine serum. Cell systems were based on reconstitution of 
the multimeric NOX1 complex containing NOX1, NOXO1 and NOXA1 in HCT116 cells. 
PcDNA3.1-hNox1, pcDNA3.1-hNoxa1 and pcDNA3.1-hNoxo1 were kind gifts from 
Botond Banfi & Karl-Heinz Krause (Addgene plasmid # 58344, # 58531 and # 58530).19, 58 
Mutations were introduced using site-directed mutagenesis and were verified by sequencing 
(Eurofins Genomics). HCT116 cells were transfected with Lipofectamine 2000 (Invitrogen) 
following manufacturer’s instruction. Expression of wild-type and NOX1 variants was 
confirmed by quantitative PCR. ROS production was analyzed by L-012 enhanced 
chemiluminescence 48 hours post-transfection.
ROS assays
ROS generation by colonic epithelial biopsies, organoid cells and transiently transfected 
HCT116 cells was measured using L-012 enhanced chemiluminescence (Wako laboratories). 
After washing with PBS, cells or biopsies were pre-incubated in L-012 (100 µM) for 10 
minutes, followed by stimulation with Phorbol 12-myristate 13-acetate (PMA, 5 µg/mL, 
Sigma) or addition of diphenyleneiodonium (DPI, 10 µM, Sigma) and 2-acetylphenothiazine 
(ML171, 10 µM, Tocris) in indicated conditions. Emission of light was recorded at baseline 
and thereafter as a kinetic assay every 1–10 minutes in opaque white 96-well plates 
(FLUOstar OPTIMA, BMG labtech).
For standardization, all intestinal epithelial biopsies were collected using Olympus Endojaw 
needle forceps with a cup-opening size of 7.2 mm and analyzed within 90 minutes of 
collection with minimal handling. Organoids were trypsinised into single cell suspension 
using TrypLETM express (Gibco), counted and equal cell numbers dispensed into white 96-
well plates.
For microscopy of ROS-producing epithelial cells, ex vivo colonic biopsies were incubated 
with 100 µg/mL nitroblue tetrazolium chloride (NBT, Sigma) in PBS-glucose (1 g/L) with or 
without NADPH-oxidase inhibitors. After 60 minutes incubation, formation of formazan 
was analyzed by light microscopy (Carl Zeiss Axioskop2, 200× magnification) on glass 
slides without cover slips. Images were photographed using Q-Imaging software. 
Microscopy images were cropped and analyzed using ImageJ software.59
Disease activity amongst IBD patients was characterized as active or quiescent on the basis 
of clinical symptoms (diarrhea, rectal bleeding, and abdominal pain), endoscopic features 
(mucosal vascular pattern, bleeding, or ulceration), histological features (cryptitis and crypt 
abscesses, lamina propria polymorphomuclear cell infiltrate), and serum biomarkers (C-
reactive protein).
Data and statistical analysis
All the data analyses were performed using GraphPad Prism version 5.02 (GraphPad 
Software, San Diego, California, USA) or R (The Foundation for Statistical Computing, R 
version 3.2.2). Unpaired data were compared using Mann-Whitney U test and paired data 
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were compared with Wilcoxon signed-rank test. Significance of differences between 
multiple groups was performed with ANOVA and post-test correction with Dunnet. Genetic 
association testing in cases and controls was conducted with the ALLELIC test.60 Pooled 
analyses were performed on the summed allele counts of different cohorts. P-values of less 
than 0.05 after correction for multiple testing were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Clinical phenotype of the NOX1 p.N122H patient and NOX1 contribution to baseline 
ROS within colonic crypts
(a) Endoscopy and histology from NOX1 mutant patient. Colonoscopy shows loss of 
vascular pattern, ulceration and luminal bleeding (left). H&E stain of colonic biopsies shows 
crypt architectural distortion and dense inflammatory cell infiltrate in the lamina propria 
(scale bar 50 µm, middle). Magnification of NOX1 mutant epithelial crypt demonstrates 
elongated nuclei (black arrow head) and crypt abscesses (white arrow head, right). (b) 
Family pedigree and Sanger sequencing of NOX1 gene around the mutation site in a wild-
type control and family members. (c) NOX1 protein sequence alignment of different genera 
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showing the evolutionary conserved asparagine at position 122. (d) The NOX1 variant 
p.N122H affects all three isoforms of NOX1. Amino acid sequence was aligned using 
ClustalW. (e) Analysis of NOX1, NOXA1 and NOXO1 expression by quantitative PCR in 
biopsies of the gastrointestinal tract. Single biopsies per segment were obtained from 4–7 
non-inflamed individuals. Bars represent mean. Statistical significance was determined by 
Mann-Whitney U test. (f) Ex-vivo colonic biopsies (within 90 minutes of collection) were 
incubated with nitroblue tetrazolium (NBT) in PBS-Glucose at room temperature. Biopsy 
specimens were analyzed using light microscopy immediately after 60 minutes NBT 
incubation (top left, biopsy overview showing dark crypts containing reduced formazan; 
bottom, ring-like deposition of formazan at epithelial margin of crypts; top right, single 
colonic epithelial crypt captured longitudinally at high magnification). (g) Microscopy of 
ROS-producing epithelial cells in colonic crypts of ex-vivo biopsies detected by NBT dye 
(200× magnification). After 60 minutes of incubation a ring-like deposition of formazan at 
the epithelial margin of crypts was evident. In indicated conditions biopsies were co-
incubated with either a NOX1 inhibitor (ML171) or a non-specific NAPDH oxidase 
inhibitor (DPI), to verify the signal. (h, left) DPI or ML171 inhibit superoxide generation 
and L-012-enhanced chemiluminescence on colonic biopsy specimens ex-vivo. Following 
the detection of superoxide at baseline, DPI, ML171 or vehicle were added (black arrow) 
and chemiluminescence was recorded over 60 minutes. For each biopsy light emission was 
normalized to baseline reading. Data represent mean of 9 biopsies per condition obtained 
from 5 non-inflamed controls. (h, right) Results of kinetic assay calculated as AUC per 
patient. Statistical significance was determined by Mann-Whitney U test.
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Figure 2. NOX1 p.N122H diminishes epithelial ROS in primary organoids
(a) Superoxide generation of colonic epithelial biopsies measured over 60 minutes by 
L-012-enhanced chemiluminescence and total light emission quantified by area under the 
curve (AUC). Results are derived from 17 patients with colonic Crohn’s disease (active 
disease n = 10), 11 patients with ulcerative colitis (active disease n = 6), 16 non-inflamed 
controls and the patient with NOX1 p.N122H mutation. One symbol represents the mean of 
1–3 pan-colonic biopsy specimens (both right and left sided) per patient. Active versus 
quiescent disease dichotomised according to composite assessment including endoscopic 
appearance (mucosal ulceration, loss of vascular pattern, bleeding), biomarkers (CRP), and 
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histology (density of inflammatory infiltrate, cryptitis, crypt abscesses). Statistical 
significance was determined by Mann-Whitney U test. (b) Organoids from patient with 
NOX1 mutation and IBD control patient were generated from colonic biopsies obtained 
during quiescent disease state. Representative images of endoscopy, histology (H&E 
staining, scale bar 50 µm), and organoids are displayed. (c) Analysis of NADPH oxidases 
and certain subunits by quantitative PCR in NOX1 patient and IBD control organoids. (d) 
Kinetic assay of PMA-activated L-012-enhanced chemiluminescence on NOX1 mutant, IBD 
control and non-inflamed control organoid cells. Relative light units (RLU) were measured 
over 60 minutes. Results are representative of 2 independent experiments measured in 
replicates. Statistical significance was determined by Wilcoxon signed-rank test comparing 
the AUC.
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Figure 3. Comparative analysis of NOX1 variants
(a, b) Generation of superoxide in colonic epithelial cell line HCT116 reconstituted with 
multimeric NADPH oxidase complex and expressing wild-type or variant NOX1. ROS was 
analyzed by L-012-enhanced chemiluminescence in the absence (a) or presence of PMA (b). 
Chemiluminescence was measured 48 hours post-transfection and recorded over 60 minutes. 
Results represent eight independent experiments with 3–4 replicates. Each dot represents 
one replicate. Experiments were normalized to mean relative light units (RLU) without 
PMA. Line represents mean. Statistical significance was determined with ANOVA and post-
test correction performed with Dunnett (multiple comparisons to one single control).
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Figure 4. NOX1 population frequencies and genetic variation
(a) Allele frequency of NOX1 p.D360N in different populations according to Exome 
Aggregation Consortium (ExAC) data and published literature.13 (b) Number of 
hemizygotes found for a given variant (missense, nonsense, frameshift) in NOX2 and NOX1 
is blotted according to amino acid position (X-axis). Frequency is based on ExAC data. (c) 
Probability of loss of-function intolerance (pLI) of 727 human X-chromosomal genes based 
on ExAC data. X-linked primary immunodeficieny genes and NOX1 gene are highlighted.
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